Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
IPO Year:
Exchange: NASDAQ
Website: zentaris.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/25/2021 | $2.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of AEterna Zentaris with a rating of Buy and set a new price target of $2.00
6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)
6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)
6-K - Aeterna Zentaris Inc. (0001113423) (Filer)
6-K - Aeterna Zentaris Inc. (0001113423) (Filer)
6-K - Aeterna Zentaris Inc. (0001113423) (Filer)
6-K - Aeterna Zentaris Inc. (0001113423) (Filer)
6-K - Aeterna Zentaris Inc. (0001113423) (Filer)
EFFECT - Aeterna Zentaris Inc. (0001113423) (Filer)
EFFECT - Aeterna Zentaris Inc. (0001113423) (Filer)
EFFECT - Aeterna Zentaris Inc. (0001113423) (Filer)
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc.", effective as of August 6, 2024 (the "Name Change"). In addition, the Company announces that, effective as of August 9, 2024, the Company's common shares (the "Common Shares") will begin trading on the Toronto Stock
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD"). The Company confirms that the last patient conducted the last study visit succ
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") and Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro"), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the "Transaction"), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023. "This is an important day for shareholders of both companies as Aeterna and Ceapro have now officially come together to create a diversified business that is expected to create value for many years to come," said Ronald W
TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that it is making an application for an order pursuant to section 133(3) of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024 (the "Application"). The Application is scheduled to be heard before a judge of the Ontario Superior Court of Justice, Commercial List (the "Court") on June 3, 2024 at
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") announces that it has finalized certain details regarding the previously announced merger of equals transaction (the "Transaction") with Ceapro Inc. ("Ceapro"). On May 3, 2024, the Company completed a share consolidation (or reverse stock split) (the "Consolidation") of its common shares (the "Common Shares") on the basis of one post-Consolidation Common Share for every four pre-Consolidation Common Shares. As a result of the Consolidation, the exchange ratio to be used in connection with the issuance of Common Shares to Ceapro shareholders under the Transaction has
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024All-stock merger of equals transaction with Ceapro Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended March 31, 2024. Mr. Giuliano La
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") announces that it has filed articles of amendment to effect the previously announced share consolidation (or reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one post-Consolidation Common Share for every four pre-Consolidation Common Shares. The Consolidation was approved by shareholders of Aeterna at the Company's special meeting of shareholders held on March 12, 2024 along with other matters related to the merger of equals transaction with Ceapro Inc. ("Ceapro") pursuant to a plan of arra
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the "Transaction"). The parties anticipate completing the Transaction in the second quarter of 2024, subject to obtaining all required approvals and satisfying all required conditions. Further disclosure on the Transaction can be found in the respective m
AEterna Zentaris (NASDAQ:AEZS) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(0.81) by 485.19 percent. This is a 35.04 percent decrease over losses of $(3.51) per share from the same period last year.
AEterna Zentaris (NASDAQ:AEZS) reported its Q4 earnings results on Wednesday, March 27, 2024 at 08:05 AM. Here's what investors need to know about the announcement. Earnings AEterna Zentaris missed estimated earnings by -20.0%, reporting an EPS of $-1.16 versus an estimate of $-0.97. Revenue was down $2.36 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.24 which was followed by a 6.0% drop in the share price the next day. Here's a look at AEterna Zentaris's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.61 -0.87 -1.07 -0.93 EPS Actual -0.85 -0.52 -0.88 -0.84 Revenue Estimate 2.30M 1.14M 900K
AEterna Zentaris (NASDAQ:AEZS) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.97) by 19.59 percent. The company reported $100.000 thousand in sales this quarter. This is a 95.98 percent decrease over sales of $2.485 million the same period last year.
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the appointment of Giuliano La Fratta as Senior Vice President, Chief Financial Officer. Effective January 24th, 2022, Mr. La Fratta will be responsible for the finance-related leadership functions, succeeding Ms. Leslie Auld, the Company's current Senior Vice President,
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology CHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the appointment of Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer.Dr. Teifel is a leading industry executive with a career spanning over 20 years in various therapeutic areas, including endocrinology and oncology. He has
SC 13G - Aeterna Zentaris Inc. (0001113423) (Subject)
SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)
SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)
SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)